About Tokai Pharmaceuticals
Tokai Pharmaceuticals, Inc. is a United States-based biopharmaceutical company. The Company focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. The Company's lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a mechanism called androgen receptor degradation, including impairing the function of androgen receptors. The Company is developing galeterone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Androgen Receptor Modulation Optimized for Response (ARMOR) is its clinical development program for the evaluation of galeterone in patients with prostate cancer. Its drug discovery platform, androgen receptor degradation agents (ARDA), enables the Company to identify and develop compounds with potent androgen receptor degradation activity.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: TKAI
- Previous Close: $0.89
- 50 Day Moving Average: $0.976
- 200 Day Moving Average: $1.144
- 52-Week Range: $22,641,000.00 - $0.73
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.14
- P/E Growth: 0.010
- Market Cap: $20.13M
- Outstanding Shares: 22,641,000
- Beta: 1
- Return on Equity: -99.29%
- Return on Assets: -86.48%
Companies Related to Tokai Pharmaceuticals:
- Current Ratio: 5.73%
- Quick Ratio: 5.73%
What is Tokai Pharmaceuticals' stock symbol?
Tokai Pharmaceuticals trades on the NASDAQ under the ticker symbol "TKAI."
Where is Tokai Pharmaceuticals' stock going? Where will Tokai Pharmaceuticals' stock price be in 2017?
6 equities research analysts have issued 1 year price objectives for Tokai Pharmaceuticals' shares. Their predictions range from $1.15 to $16.00. On average, they expect Tokai Pharmaceuticals' share price to reach $9.72 in the next year.
When will Tokai Pharmaceuticals announce their earnings?
Tokai Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August, 12th 2016.
Who owns Tokai Pharmaceuticals stock?
Tokai Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.59%) and State Street Corp (0.61%). Company insiders that own Tokai Pharmaceuticals stock include Bioventures Ltd Novartis, Jodie Pope Morrison, John S Mcbride, Lee Kalowski and Stephen Jr Buckley.
Who bought Tokai Pharmaceuticals stock? Who is buying Tokai Pharmaceuticals stock?
Tokai Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and State Street Corp.
How do I buy Tokai Pharmaceuticals stock?
Shares of Tokai Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Tokai Pharmaceuticals stock cost?
One share of Tokai Pharmaceuticals stock can currently be purchased for approximately $0.89.